STAT+: Amgen’s Repatha linked to fewer heart attacks — SkimNews
Get the Culture newsletter
Daily culture — film, music, books, the trends and ideas worth your attention. Free.
- Novartis disclosed seven previously unreported cases of tumors in children who had received Zolgensma.
- Zolgensma is a gene therapy for spinal muscular atrophy that was approved in 2019.
- Novartis has received nine tumor reports in all since the treatment’s approval.
- Ed Silverman co-wrote STAT’s report with Jason Mast.
Why it matters: For Novartis and families using Zolgensma, the disclosure adds seven cases to a nine-report post-approval record dating to 2019. The excerpt documents tumors in children who received the gene therapy but does not state that Zolgensma caused them, leaving causation unestablished.
Ask SkimNews
